Adding a second drug improved tumor response rate and survival rate in advanced non-small cell lung cancer (NSCLC). Adding a third drug had a weaker effect on tumor response and no effect on survival

This review has been withdrawn.

The reason for withdrawal and previous versions are archived and accessible within the withdrawn record in the Cochrane Library.

Published:

18 April 2012

Authors:

Delbaldo C, Michiels S, Rolland E, Syz N, Soria J-C, Le Chevalier T, Pignon JP

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Delbaldo C, Michiels S, Rolland E, Syz N, Soria J-C, Le Chevalier T, Pignon JP. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No.: CD004569. DOI: 10.1002/14651858.CD004569.pub3